Rheumatoid Arthritis Patients with Sjogrens Syndrome are More Prone to Depression than Patients with Rheumatoid Arthritis or Sjogrens Syndrome Alone

Miwa, Yusuke; Hosaka, Michio; Wakabayashi, Kunibobu; Odai, Tsuyoshi; Isozaki, Takeo; Matsunawa, Mizuho; Yajima, Nobuyuki; Shiozawa, Fumitaka; Hanaoka, Ryosuke; Negishi, Masao; Ide, Hirotsu; Kasama, Tsuyoshi; Adachi, Mitsuru

doi:10.2174/157339708783497973

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complications with Sjögren's syndrome (17), fibromyalgia (18) and the effect of other combined drugs should also be considered. Biologics exhibit a good therapeutic effect in RA patients who do not sufficiently respond to MTX.…”

Section: Discussionmentioning

confidence: 99%

Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients

et al. 2016

Self Cite

View full text Add to dashboard Cite

Objective We examined whether infliximab (IFX) therapy was more effective than methotrexate (MTX) monotherapy to achieve an improvement in depressive states in Rheumatoid Arthritis (RA) patients. Methods We examined 152 RA patients (72 IFX patients and 80 MTX patients).We conducted an openlabel cohort study to evaluate the disease activity of RA (Simplified Disease Activity Index; SDAI), depressive states (Hamilton Rating Scale for Depression; HAM-D), Activity of Daily Living (ADL) (modified Health Assessment Questionnaire; mHAQ) and Quality of Life (QOL) [Short Form (SF)-36] in patients before and 6 months after receiving therapy. The HAM-D, SDAI, mHAQ and SF-36 scores after 6 months of therapy were measured as the outcomes. Results We analyzed 60 IFX patients and 53 MTX patients. The HAM-D scores significantly improved in both groups (p<0.001), but there was no significant difference in the effectiveness between the IFX and MTX therapies (p=0.792). The SDAI scores significantly improved in both groups after therapy (p<0.001), and IFX therapy was more effective than MTX therapy (p=0.004). The mHAQ and HAM-D scores also improved significantly in both groups after therapy (p<0.001), but no significant difference in the effectiveness between the IFX and MTX therapies was observed (p=0.272, 0.792). The scores of all 8 items of the SF-36 improved in both groups after therapy, but IFX therapy was more effective than MTX therapy in only 4 of the 8 items (p<0.05). Conclusion Both IFX and MTX therapy improved the clinical efficacy, ADL, QOL and depressive states. However, no significant differences regarding an improvement in the depressive states and ADL were observed between IFX therapy and MTX monotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Rheumatoid Arthritis Patients with Sjogrens Syndrome are More Prone to Depression than Patients with Rheumatoid Arthritis or Sjogrens Syndrome Alone

Abstract: Although depression is known to be an important complication in patients with rheumatoid arthritis (

Cited by 1 publication

References 30 publications

Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients

Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients

Contact Info

Product

Resources

About